Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
- Conditions
- End-stage Renal Disease (ESRD)Kidney Disease
- Interventions
- Other: DIANEALOther: EXTRANEAL
- Registration Number
- NCT01228279
- Lead Sponsor
- Ottawa Hospital Research Institute
- Brief Summary
Hypothesis:
Patients starting peritoneal dialysis with a glucose-based regimen have high sympathetic activity in response to an increase in leptin and insulin. Converting patients from a regimen of only glucose containing dialysate to a regimen with non-glucose-based solution, icodextrin, will reduce the insulin and leptin levels and will reverse dialysis-induced increases in sympathetic activity.
- Detailed Description
Cardiovascular mortality remains higher among patients treated with peritoneal dialysis as compared to patients treated with hemodialysis. Sympathetic hyperactivity is considered a significant emerging risk factor for cardiovascular mortality among patients with ESRD (End-Stage Renal Disease). Sympathetic activity, via its hemodynamic effects and trophic effects, and in interaction with RAAS (Renin Angiotensin Aldosterone System), does play a major role in cardiac and vascular remodelling, development of LVH and vascular hypertrophy, as well as progression to CHF. Glucose-based dialysate induces hyperinsulinemia and hyperleptinemia. We propose that hyperleptinemia induced by glucose-based peritoneal solution is a significant contributing factor to sympathetic hyperactivity in ESRD patients treated with PD, and could be prevented by non-glucose-based PD solution such as icodextrin-based.
Adult patients with ESRD starting PD as their first renal replacement therapy modality will be studied. Patients will be recruited 1-3 weeks prior to starting PD treatment. At baseline, specific studies for microneurography (MSNA), fasting plasma insulin, leptin, catecholamines and brain natriuretic peptide (BNP) will be performed. EKG will be recorded and digitized for further assessment of heart rate variability using power spectral analysis. Extracellular fluid volume status will be assessed by bioelectrical impedance. Central vascular volume will be assessed from inferior vena cava (IVC) by heart ultrasound. Consequently 24-h ambulatory blood pressure monitoring(ABPM)and a 24-h urine collection for urea clearance and creatinine clearance will be done.
All participants into the study will receive a PD treatment for 6 weeks with standard glucose-based PD solution Dianeal. The specific studies are repeated at 6 weeks.Then, patients will be randomized to one of the two groups (arms). One group will continue with Dianeal PD solution for another 12 weeks. The other group will receive Dianeal during the day and Extraneal, icodextrin or non-glucose based solution, during the night only, for the next 12 weeks. The specific studies are repeated at 12 weeks after randomization (18 weeks of PD treatment).
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
- Adult (age 18 years and older)
- Patients with end-stage renal disease(ESRD)/chronic kidney disease(CKD)stage 5
- Diabetes Mellitus
- Acute coronary syndrome in the past 6 months
- Cardiac arrhythmias (2nd and 3rd degree heart block or premature ventricular complexes in Lown classes 4 or 5)
- Symptoms suggestive of obstructive or central sleep apnea (with a score of > 10 on Epworth sleepiness scale)
- Patients taking Clonidine
- Body mass index (BMI) > 34
- Patients unable to give consent
- Pregnant women
- Patients with leg injury involving nerve damage
- Patients taking anticoagulant medication
- Patients with significant bleeding disorder or liver disorder
- Hemoglobin <1.05 g/dl at the time of initiation of therapy
- patients with unilateral or bilateral nephrectomy
- Planned kidney transplant in the next 4 months
- Life expectancy under 6 months
- Oliguria (urine output less than 400 ml per day)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description DIANEAL DIANEAL One group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with the same type of solution for another 12 weeks. EXTRANEAL EXTRANEAL The other group of patients will start peritoneal dialysis with the glucose-based solution (DIANEAL) for 6 weeks, then will continue with DIANEAL solution during the day and the non-glucose-based solution, EXTRANEAL, during the night
- Primary Outcome Measures
Name Time Method Changes in muscle sympathetic nerve activity(MSNA) 6 weeks on PD and 18 weeks on PD Muscle sympathetic nerve activity(MSNA) is measured by microneurography at
* baseline (before starting peritoneal dialysis)
* 6 weeks of PD
* 18 weeks of PD(12 weeks after randomization)
MSNA increases on a glucose-based dialysis regimen and may decrease by adding non-glucose-based solutionChanges in leptin levels 6 weeks on PD and 18 weeks on PD Plasma leptin increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
- Secondary Outcome Measures
Name Time Method Changes in BNP (Brain Natriuretic Peptide)levels 6 weeks on PD and 18 weeks on PD \*Brain Natriuretic Peptide (BNP)increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
Changes in plasma catecholamines levels 6 weeks on PD and 18 weeks on PD \*Plasma catecholamines (epinephrine and norepinephrine) increase on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
Changes in extracellular volume assessed by bioelectrical impedance (BIA) 6 weeks on PD and 18 weeks on PD Bioelectrical impedance directly measures extracellular fluid volume and total body water. The test is based on the ability to detect differences in the conductive properties of a cell by measuring its resistance (impedance) to electrical current. The technique is reliable for tracking sequential changes in extracellular fluid volume.
Changes in heart rate variability 6 weeks on PD and 18 weeks on PD During the microneurography testing, EKG is recorded. Heart rate and heart rate variability(HRV) will be analyzed from EKG data at baseline, 6 weeks and 18 weeks after starting dialysis.
Changes in blood pressure as assessed from 24-hour ambulatory blood pressure monitor (ABPM) 6 weeks on PD and 18 weeks on PD Blood pressure will be assessed with 24-hour ABPM at baseline, 6 weeks on PD and 18 weeks after starting peritoneal dilaysis. Summary measures of each day and night period include average systolic and diastolic BP as well as % nocturnal dipping. These summary measures can predict cardiovascular events more accurately than casual BP measures
Changes in central intravascular volume assessed by cardiac ultrasound 6 weeks on PD and 18 weeks on PD Central intravascular volume will be assessed by measuring inferior vena cava (IVC) diameter during cardiac ultrasound at baseline, 6 weeks and 18 weeks on dialysis treatment
Changes in plasma insulin levels 6 weeks on PD and 18 weeks on PD \*Plasma insulin increases on a glucose-based peritoneal dialysis regimen and may decrease by adding non-glucose-based solution to the dialysis regimen
Trial Locations
- Locations (1)
Ottawa Hospital Research Institute
🇨🇦Ottawa, Ontario, Canada